Teva Pharmaceutical Industries has been granted a patent for a system that assesses the probability of asthma exacerbations. The system utilizes an inhaler equipped with sensors to track inhalation frequency and airflow parameters, employing a machine learning model to generate notifications regarding exacerbation risks based on collected data. GlobalData’s report on Teva Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Teva Pharmaceutical Industries, Cancer treatment biomarkers was a key innovation area identified from patents. Teva Pharmaceutical Industries's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Asthma exacerbation probability determination system and method
The patent US12036359B2 outlines a method and system for predicting asthma exacerbations using a smart inhaler equipped with sensors. The method involves monitoring the number of inhalations and airflow parameters, such as peak inhalation flow, inhalation volume, and inhalation duration, over a specified period, typically the previous four days. A trained machine learning model analyzes this data to calculate the probability of an asthma exacerbation, which is then communicated to the user through a notification on a display device. The system can also assess night-time inhalations and compare current airflow parameters to baseline values to enhance prediction accuracy.
Additionally, the patent describes the potential for updating a user's treatment regimen based on the predicted probability of an exacerbation. If the probability exceeds a predetermined threshold, the system may recommend the administration of biologics, such as mepolizumab or dupilumab. The inhaler is designed with a processor, memory, and transceiver to facilitate data collection and communication, ensuring that users receive timely alerts regarding their asthma management. This innovative approach aims to improve patient outcomes by enabling proactive interventions based on real-time inhalation data.
To know more about GlobalData’s detailed insights on Teva Pharmaceutical Industries, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
